Agenus (FRA:AJ8) Total Liabilities : €411.1 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Agenus Total Liabilities?

Agenus's Total Liabilities for the quarter that ended in Mar. 2024 was €411.1 Mil.

Agenus's quarterly Total Liabilities increased from Sep. 2023 (€422.37 Mil) to Dec. 2023 (€423.93 Mil) but then declined from Dec. 2023 (€423.93 Mil) to Mar. 2024 (€411.13 Mil).

Agenus's annual Total Liabilities increased from Dec. 2021 (€369.97 Mil) to Dec. 2022 (€442.22 Mil) but then declined from Dec. 2022 (€442.22 Mil) to Dec. 2023 (€423.93 Mil).

Agenus Total Liabilities Historical Data

The historical data trend for Agenus's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agenus Total Liabilities Chart

Agenus Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

348.01

350.18

369.97

442.22

423.93

Agenus Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															435.21	424.91	422.37	423.93	411.13

Agenus Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Agenus's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	234.658	+	(69.031	+	119.188
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1.048	+	0)
	=	423.9

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	287.858	-	-136.066
	=	423.9

Agenus's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	235.522	+	(56.816	+	117.741
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1.052	+	0)
	=	411.1

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	236.034	-	-175.097
	=	411.1

Agenus Total Liabilities Related Terms

Thank you for viewing the detailed overview of Agenus's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Agenus (FRA:AJ8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (FRA:AJ8) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

AGEN:USA AJ81:Germany

Address

3 Forbes Road, Lexington, MA, USA, 02421

Website

https://www.agenusbio.com

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Agenus (FRA:AJ8) Headlines

No Headlines